SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a number one medical genetics firm, immediately introduced the addition of instruments from Medneon, a digital well being AI firm, to its sturdy medical workflow and affected person schooling instruments. The extra capabilities additional help clinicians and sufferers with most cancers by making it simpler to find out who ought to get testing and the right way to use genetic data to individualize therapy.
“Whereas utility of genetic data in most cancers care is nicely established, it stays difficult for clinicians to navigate various pointers and analysis findings that inform them about which affected person, which check and what outcomes imply for affected person care,” mentioned Robert Nussbaum, M.D., chief medical officer at Invitae. “The addition of Medneon’s danger evaluation device, which was developed by consultants within the area, makes it simpler for clinicians to ensure testing is taken into account and findings are acted upon for all sufferers who may benefit from genetic-informed care. The frequent updating of Medneon’s suggestions based mostly on probably the most present suggestions and latest analysis findings implies that suppliers and sufferers can have probably the most up-to-date data at their disposal.”
Medneon’s Predictive Threat Evaluation™ combines a number of components, together with present pointers, real-world proof, and private and household historical past, to quickly determine a person’s elevated short-term and lifelong most cancers danger. Clinicians are shortly knowledgeable of their affected person’s eligibility for genetic testing and supplemental imaging, in order that preventative motion could also be taken. As well as, the platform can help clinicians in confirming and documenting the clinician’s willpower that the affected person met medical necessity qualifying standards to assist navigate insurance coverage protection. When check outcomes are returned, the corporate’s Customized Genetic Insights™ curates data from an array of printed knowledgeable assets, together with the AI data base ASK2ME™, medical consultants, and genetic counselors, to generate customized experiences that help sufferers and clinicians in shared decision-making.
“For clinicians who’re studying to handle care by way of telemedicine throughout the ongoing pandemic, the Medneon platform distills the quickly rising quantity of printed genetic and genomic data into digestible experiences to assist decide when to order a check, the right way to interpret outcomes and the right way to personalize a care plan,” mentioned Noel Pugh, Ph.D., JD, MHA, head of commercialization at Medneon. “We hope by using these instruments, preventable cancers will probably be caught earlier to in the end ship higher outcomes for sufferers and their households.”
Medneon’s applied sciences are one other addition to the instruments Invitae presents, anchored by its Gia platform, that help sufferers and suppliers by offering affected person schooling and medical help all through the genetic testing course of throughout a wide selection of medical areas.
About Medneon
Medneon’s mission is to stop most cancers and optimize therapy by empowering people and their care staff with DNA insights and choice help instruments all through the most cancers journey. The revolutionary Medneon digital platform combines AI and human insights with actionable data concerning a person’s most cancers danger to tell precision prevention and administration over time on the point-of-care or by way of telemedicine. For extra data, go to the corporate’s web site at www.medneon.com.
About Invitae
Invitae Company (NYSE: NVTA) is a number one medical genetics firm, whose mission is to carry complete genetic data into mainstream medication to enhance healthcare for billions of individuals. Invitae’s purpose is to mixture the world’s genetic assessments right into a single service with greater high quality, sooner turnaround time, and decrease costs. For extra data, go to the corporate’s web site at invitae.com.
Secure Harbor Assertion
This press launch incorporates forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995, together with statements referring to the capabilities and potential advantages of the instruments offered by Medneon. Ahead-looking statements are topic to dangers and uncertainties that might trigger precise outcomes to vary materially, and reported outcomes shouldn’t be thought of as a sign of future efficiency. These dangers and uncertainties embrace, however are usually not restricted to: the corporate’s historical past of losses; the corporate’s skill to compete; the corporate’s failure to handle progress successfully; the corporate’s must scale its infrastructure prematurely of demand for its assessments and to extend demand for its assessments; the corporate’s skill to make use of quickly altering genetic knowledge to interpret check outcomes precisely and persistently; safety breaches, lack of knowledge and different disruptions; legal guidelines and laws relevant to the corporate’s enterprise; and the opposite dangers set forth within the firm’s filings with the Securities and Alternate Fee, together with the dangers set forth within the firm’s Quarterly Report on Type 10-Q for the quarter ended September 30, 2020. These forward-looking statements communicate solely as of the date hereof, and Invitae Company disclaims any obligation to replace these forward-looking statements.
Contact:
Laura D’Angelo
[email protected]
(628) 213-3283
SOURCE Invitae Company
Associated Hyperlinks
— to www.prnewswire.com
